Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ITRM Stock Forecast 2026-2027
$0.33
Current Price
$17.37M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ITRM Price Targets
+2,660.7%
To High Target of $9.00
+1,587.1%
To Median Target of $5.50
+513.5%
To Low Target of $2.00
ITRM Price Momentum
-2.9%
1 Week Change
-21.4%
1 Month Change
-79.4%
1 Year Change
-2.9%
Year-to-Date Change
-81.4%
From 52W High of $1.75
+25.4%
From 52W Low of $0.26
📊 TOP ANALYST CALLS
Did ITRM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Iterum is one of their latest high-conviction picks.
Latest ITRM Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, ITRM has a bullish consensus with a median price target of $5.50 (ranging from $2.00 to $9.00). The overall analyst rating is N/A (N/A/10). Currently trading at $0.33, the median forecast implies a 1,587.1% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 2,660.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ITRM Analyst Ratings
2
Buy
0
Hold
0
Sell
ITRM Price Target Range
Low
$2.00
Average
$5.50
High
$9.00
Current: $0.33
Latest ITRM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ITRM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 8, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Assumes | $9.00 |
| Sep 10, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $5.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $5.00 |
| Jun 21, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| May 31, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| May 14, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| Apr 30, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| Apr 1, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| Mar 6, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| Feb 7, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Upgrade | $6.00 |
| Jul 27, 2021 | Gabelli & Co. | Kevin Kedra | Hold | Upgrade | $N/A |
| Jul 26, 2021 | HC Wainwright & Co. | Ed Arce | Neutral | Downgrade | $N/A |
| May 28, 2021 | Gabelli & Co. | Hold | Upgrade | $N/A | |
| Mar 15, 2021 | HC Wainwright & Co. | Buy | Upgrade | $N/A | |
| Oct 1, 2020 | SVB Leerink | Ami Fadia | Market Perform | Maintains | $1.50 |
| Jun 16, 2020 | HC Wainwright & Co. | Neutral | Downgrade | $N/A | |
| Jun 2, 2020 | SVB Leerink | Market Perform | Maintains | $1.00 | |
| Jun 2, 2020 | RBC Capital | Sector Perform | Downgrade | $2.00 | |
| Dec 11, 2019 | RBC Capital | Gregory Renza | Outperform | Maintains | $10.00 |
| Dec 11, 2019 | SVB Leerink | Ami Fadia | Market Perform | Downgrade | $4.00 |
Iterum Therapeutics plc (ITRM) Competitors
The following stocks are similar to Iterum based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ITRM
Iterum Therapeutics
mkt cap
17.48M
Iterum Therapeutics plc (ITRM) Financial Data
Iterum Therapeutics plc has a market capitalization of $17.37M with a P/E ratio of -0.3x. The company generates $390,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -1,982.3% and return on equity of +607.1%.
Valuation Metrics
Market Cap
$17.37M
Enterprise Value
$40.47M
P/E Ratio
-0.3x
PEG Ratio
0.0x
Price/Sales
46.3x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
+94.9%
Operating Margin
-1,982.3%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+63.8%
Current Ratio
2.1x
Debt/Equity
-4.6x
ROE
+607.1%
ROA
-53.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Iterum Therapeutics plc (ITRM) Business Model
About Iterum Therapeutics plc
What They Do
Develops antibiotics for drug-resistant bacterial infections.
Business Model
Iterum Therapeutics operates as a clinical-stage pharmaceutical company that focuses on developing innovative antibiotics, particularly for multi-drug resistant Gram-negative infections. The company generates revenue primarily through the development and eventual commercialization of its flagship product, sulopenem, which targets specific bacterial infections.
Additional Information
Headquartered in Dublin, Ireland, Iterum is positioned in a critical market addressing the urgent need for new treatment options amidst rising antibiotic resistance. The company’s advancements not only enhance patient care but also influence global healthcare policies, underscoring its significance in the pharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
9
CEO
Mr. Corey N. Fishman
Country
Ireland
IPO Year
2018
Website
www.iterumtx.comIterum Therapeutics plc (ITRM) Latest News & Analysis
Latest News
Iterum Therapeutics Provides Business Update
23 days ago
Quick Summary
Iterum Therapeutics has announced an expansion in market access for ORLYNVAH™, with a major PBM agreement enhancing payor reimbursement and contracting for its antibiotic treatments.
Why It Matters
Iterum's expansion in market access and major PBM agreements enhance revenue potential and competitive positioning, signaling growth opportunities in the antibiotic sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Iterum Therapeutics plc (ITRM) will hold its Q3 2025 earnings call on November 14, 2025, at 8:30 AM EST, featuring key executives and analysts from various firms.
Why It Matters
The earnings call provides insights into Iterum Therapeutics' financial health and strategic direction, impacting stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Iterum Therapeutics launched ORLYNVAH™ in the U.S. in August 2025 for treating uncomplicated urinary tract infections. The company extended its cash runway into Q2 2026 and will host a conference call today.
Why It Matters
The launch of ORLYNVAH™ signals potential revenue growth for Iterum, while an extended cash runway indicates improved financial stability, enhancing investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025
2 months ago
Quick Summary
Iterum Therapeutics will release Q3 2025 financial results on November 14, 2025, before U.S. market open, followed by a conference call at 8:30 a.m. ET to discuss results and business updates.
Why It Matters
The upcoming financial results and conference call from Iterum Therapeutics may indicate the company's performance and strategic direction, influencing investor sentiment and stock price movements.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Iterum Therapeutics to Present Data at IDWeek 2025
3 months ago
Quick Summary
Iterum Therapeutics will present two posters at IDWeek 2025 in Atlanta from October 19-22, focusing on their antibiotics for multi-drug resistant infections.
Why It Matters
The presentation of data at a prominent conference highlights Iterum Therapeutics' advancements in antibiotic treatments, potentially boosting investor confidence and stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.
4 months ago
Quick Summary
The FDA has approved a novel oral antibiotic with penem-like efficacy, providing a new treatment option for uncomplicated urinary tract infections.
Why It Matters
The FDA approval of a new antibiotic enhances market competition, potentially boosting sales for the company involved and impacting stock prices in the pharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ITRM Stock
What is Iterum Therapeutics plc's (ITRM) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Iterum Therapeutics plc (ITRM) has a median price target of $5.50. The highest price target is $9.00 and the lowest is $2.00.
Is ITRM stock a good investment in 2026?
According to current analyst ratings, ITRM has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.33. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ITRM stock?
Wall Street analysts predict ITRM stock could reach $5.50 in the next 12 months. This represents a 1,587.1% increase from the current price of $0.33. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Iterum Therapeutics plc's business model?
Iterum Therapeutics operates as a clinical-stage pharmaceutical company that focuses on developing innovative antibiotics, particularly for multi-drug resistant Gram-negative infections. The company generates revenue primarily through the development and eventual commercialization of its flagship product, sulopenem, which targets specific bacterial infections.
What is the highest forecasted price for ITRM Iterum Therapeutics plc?
The highest price target for ITRM is $9.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 2,660.7% increase from the current price of $0.33.
What is the lowest forecasted price for ITRM Iterum Therapeutics plc?
Price targets from Wall Street analysts for ITRM are not currently available. The stock is trading at $0.33.
What is the overall ITRM consensus from analysts for Iterum Therapeutics plc?
The overall analyst consensus for ITRM is bullish. Out of 6 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.50.
How accurate are ITRM stock price projections?
Stock price projections, including those for Iterum Therapeutics plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 11:54 AM UTC